Test IgE immune-filter treatment for severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This Phase 2 study tests a treatment called IgE-specific immunoadsorption, which works by filtering certain immune signals in the blood. It is meant for adults with severe, long-lasting eczema that has not responded well (or could not be tolerated) to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (over 18 years old)
- Your eczema is severe (SCORAD score above 40, as measured by the study)
- Your eczema has been persistent and stable for more than 1 year
- You can sign informed consent
- You are not pregnant and will not become pregnant during the treatment
- You previously tried common eczema treatments (phototherapy and/or several immune-suppressing medicines or steroids) but they were not enough, caused too many side effects, or could not be used
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with moderate to severe eczema who are eligible for or already taking systemic (pill or injection) medicines. It does not test any new drug—it simply tracks how eczema is managed in real life, which may help improve future care.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This trial tests a new stem cell injection called ADSTEM for people with moderate to severe eczema that hasn't improved with standard treatments. The goal is to see if it can reduce eczema symptoms like itching, redness, and skin rash.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.